Stock Message Boards
ETF Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards Portfolio Channel
THRX Description — Theravance Inc

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and collaborations with pharmaceutical companies. Co. is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system / pain. Co.'s key programs include: RELVAR™/BREO™ ELLIPTA® (fluticasone furoate/vilanterol, FF/VI), ANORO™ ELLIPTA™ (umeclidinium bromide/vilanterol, UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with Glaxo Group Limited, and its Long-Acting Muscarinic Antagonist program.

Company Name:  Theravance Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding THRX:  26
Total Market Value Held by ETFs:  $136,056,892
Total Market Capitalization:  $2,090,000,000
% of Market Cap. Held by ETFs:  6.51%
 ETF   THRX Weight   THRX Amount 
 XPH   3.68%   $40,371,301         
 IBB   0.33%   $26,468,181         
 IWM   0.08%   $24,145,519         
 DES   1.19%   $14,489,409         
 IHE   1.16%   $11,731,501         
 IWO   0.15%   $11,176,525         
 BIB   0.22%   $1,421,455         
 VXF   0.03%   $1,381,105         
 JKL   0.28%   $1,210,015         
 IYH   0.05%   $946,257         
List of all 26 ETFs holding THRX »
10 ETFs With Stocks That Insiders Are Buying
25 Dividend Giants Widely Held By ETFs
25 S.A.F.E. Dividend Stocks Increasing Payments For Decades
Broker Darlings: Top 15 Analyst Picks of the Dow
Top 25 Broker Analyst Picks of the S&P 500
Forgotten S&P 500 Giants: Analysts' Current Least Favorites
25 Top Ranked Socially Responsible Dividend Stocks
10 Oversold ETFs
The Top 10 DividendRank'ed Stocks
The DividendRank Top 25
The Top 10 DividendRank'ed DJIA Components
The Top 10 DividendRank'ed Dow Transports Components
The Top 10 DividendRank'ed Dow Utilities Components
The Top 10 DividendRank'ed Nasdaq 100 Components
10 Stocks Going Ex-Dividend
10 Oversold Dividend Stocks
10 Stocks Where Yields Got More Juicy
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Top Ranked Dividend Stocks With Insider Buying
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Metals Stocks You Can Buy Cheaper Than Insiders Did
10 Oversold Metals Stocks
10 Must-Know High-Yield REITs
10 Top DividendRank'ed Financials
10 Top DividendRank'ed Metals Stocks
10 Oversold Energy Stocks
10 Top DividendRank'ed Energy Stocks
10 Top DividendRank'ed Utility Stocks
10 Stocks Crossing Below Book Value
10 Stocks Crossing Above Their 200 Day Moving Average
10 Stocks Crossing Below Their 200 Day Moving Average
10 ETFs Crossing Above Their 200 DMA
The 10 Biggest ETFs
The 10 Best ETF Performers
The 10 Worst ETF Performers
10 ETFs With Notable Inflows
10 ETFs With Notable Outflows
The Top 10 DividendRank'ed Canadian Stocks
The DividendRank Canada Top 25
10 Canadian Stocks Going Ex-Dividend
10 Oversold Canadian Stocks
10 Canadian Stocks Where Yields Got More Juicy
10 Must-Know High-Yield Canadian Real Estate Stocks
10 Top DividendRank'ed Canadian Financials
10 Must-Know High-Yield Canadian Energy Stocks
10 Canadian Stocks Crossing Below Book Value
10 Canadian Stocks Crossing Above Their 200 Day Moving Avg
10 Canadian Stocks Crossing Below Their 200 Day Moving Avg
Stock market game
Quotes delayed 20 minutes

Hold (1.74 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite


PARTNER NEWS:

Thu, Feb 26, 8:50 AM, Zacks
BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog
BioMarin Pharmaceutical's (BMRN) fourth-quarter 2014 loss of 30 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 59 cents but wider than the year-ago loss of 27 cents.

Thu, Feb 26, 8:00 AM, Zacks
Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog
Pharmacyclics Inc.'s (PCYC) shares were up 16.9% after a report from Bloomberg suggested that the company is exploring its options including a potential sale.

ETFs Holding THRX | Theravance Inc | ETF Channel | www.ETFChannel.com | Copyright © 2009 - 2015, All Rights Reserved

Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.